Dr. Stephen P. Marso
Biography & Research Background
Stephen P. Marso, MD, is a cardiologist and clinical trial leader who served as the lead investigator on the SUSTAIN-6 cardiovascular outcomes trial published in the New England Journal of Medicine (2016). SUSTAIN-6 demonstrated that semaglutide significantly reduced major adverse cardiovascular events (MACE) by 26% in patients with type 2 diabetes at high cardiovascular risk — a finding that fundamentally changed the role of GLP-1 receptor agonists in cardiovascular risk management. Stephen P. Marso is being referenced as one of the leading scientists involved in the research and development of Semaglutide. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between SHR3D Aminos and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Stephen P. Marso is referenced as a leading researcher in the following peptide research profiles on SHR3D Aminos:
Dr. Stephen P. Marso is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between SHR3D Aminos and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.